Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence

Neuropeptides

Volumn 45, Issue 3, 2011, Pages 213-218

  Kelps, Kristen A ^a   Turchan Cholewo, Jadwiga ^a   Hascup, Erin R ^a   Taylor, Tiffany L ^a   Gash, Don M ^a   Gerhardt, Greg A ^a   Bradley, Luke H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biotherapeutic; GDNF; Heparin; Neuroprotection; Propeptides

Indexed keywords

3 NITROPROPIONIC ACID; DOPAMINE NERUON STIMULATING PEPTIDE 17; DOPAMINE NEURON STIMULATING PEPTIDE 11; DOPAMINE NEURON STIMULATING PEPTIDE 5; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEPARIN; STAUROSPORINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CELL PROTECTION; CELL STRAIN HEK293; CIRCULAR DICHROISM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG SCREENING; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; NEUROPROTECTION; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; CASPASE 3; CONVULSANTS; ENZYME INHIBITORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HEK293 CELLS; HEPARIN; HUMANS; NITRO COMPOUNDS; PEPTIDES; PROPIONIC ACIDS; RATS; STAUROSPORINE;

PARKINSONIA; RATTUS;

EID: 79955591119     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2011.03.003     Document Type: Article

References (33)

1. Alfano I., Vora P., Mummery R.S., Mulloy B., Rider C.C. The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochemical Journal 2007, 404:131-140.
2. Beal M.F. Neurochemistry and toxin models in Huntington's disease. Current Opinion in Neurology 1994, 7:542-547.
3. Bell L.N. Peptide stability in solids and solutions. Biotechnology Progress 1997, 13:342-346.
4. Bradley L.H., Fuqua J., Richardson A., Turchan-Cholewo J., Ai Y., Kelps K.A., Glass J.D., He X., Zhang Z., Grondin R., Littrell O.M., Huettl P., Pomerleau F., Gash D.M., Gerhardt G.A. Dopamine neuron stimulating actions of a GDNF propeptide. PLoS ONE 2010, 5:e9752.
5. Bradley, L.H., Gash, D.M., Gerhardt, G.A., Glass, J.D., 2009. Amidated dopamine neuron stimulating peptides for CNS dopaminergic upregulation. US Patent Application #12/508,916.
6. Fiandaca M.S., Forsayeth J.R., Dickinson P.J., Bankiewicz K.S. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008, 5:123-127.
7. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Annals of Neurology 2005, 58:224-233.
8. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
9. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 2003, 9:589-595.
10. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., Oldfield E., Bankiewicz K.S. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Experimental Neurology 2001, 168:155-161.
11. Immonen T., Alakuijala A., Hytonen M., Sainio K., Poteryaev D., Saarma M., Pasternack M., Sariola H. A proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus. Experimental Neurology 2008, 210:793-796.
12. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
13. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 2006, 59:459-466.
14. 125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Research 1998, 789:9-22.
15. Lin L.-F.H., Zhang T.J., Collins F., Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. Journal of Neurochemistry 1994, 63:758-768.
16. Lin L.-F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
17. Lindner M.D., Winn S.R., Baetge E.E., Hammang J.P., Gentile F.T., Doherty E., McDermott P.E., Frydel B., Ullman M.D., Schallert T., Emerich D.F. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Experimental Neurology 1995, 132:62-76.
18. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Experimental Neurology 2008, 209:82-88.
19. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Canadian Journal of Neurological Sciences 1991, 18:492-498.
20. Morrison P.F., Lonser R.R., Oldfield E.H. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. Journal of Neurosurgery 2007, 107:74-83.
21. Nasr P., Carbery T., Geddes J. N-methyl-d-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochemical Research 2009, 34:490-498.
22. Palfi S., Ferrante R.J., Brouillet E., Beal M.F., Dolan R., Guyot M.C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. Journal of Neuroscience 1996, 16:3019-3025.
23. Parkash V., Leppanen V.M., Virtanen H., Jurvansuu J.M., Bespalov M.M., Sidorova Y.A., Runeberg-Roos P., Saarma M., Goldman A. The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: Insights into RET signaling and heparin binding. Journal of Biological Chemistry 2008, 283:35164-35172.
24. Patel N.K., Gill S.S. GDNF delivery for Parkinson's disease. Operative Neuromodulation 2007, 135-154. Springer, Vienna. D.E. Sakas, B.A. Simpson (Eds.).
25. Piltonen M., Bespalov M.M., Ervasti D., Matilainen T., Sidorova Y.A., Rauvala H., Saarma M., Männistö P.T. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Experimental Neurology 2009, 219:499-506.
26. Powell M.F. Peptide stability in aqueous parenteral formulations. Formulation and delivery of proteins and peptides 1994, 100-117. American Chemical Society. J.L. Cleland, R. Langer (Eds.).
27. Ramaswamy S., Soderstrom K.E., Kordower J.H. Trophic factors therapy in Parkinson's disease. Progress in Brain Research 2009, 201-216. Elsevier. J. Verhaagen, E.M. Hol, I. Huitenga, J. Wijnholds, A.B. Bergen, G.J. Boer, D.F. Swaab (Eds.).
28. Rickard S.M., Mummery R.S., Mulloy B., Rider C.C. The binding of human glial cell line-derived neurotrophic factor to heparin and heparan sulfate: Importance of 2-O-sulfate groups and effect on its interaction with its receptor, GFRa1. Glycobiology 2003, 13:419-426.
29. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Experimental Neurology 2006, 202:497-505.
30. Sariola H., Saarma M. Novel functions and signalling pathways for GDNF. Journal of Cell Science 2003, 116:3855-3862.
31. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. Journal of Neurosurgery 2005, 102:216-222.
32. Thorne R.G., Frey W.H.I. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clinical Pharmacokinetics 2001, 40:907-946.
33. Wang L., Muramatsu S., Lu Y., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Hanazono Y., Kume A., Urano F., Ichinose H., Nagatsu T., Nakano I., Ozawa K. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy 2002, 9:381-389.